During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other expensive stocks. We previously covered the 10 cheapest stocks insiders are buying recently.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

It is the first time that Merck has exercised an option in its collaboration with the mRNA vaccine specialist, first agreed in 2016 and expanded two years later to include additional candidates.

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

February 12, 2025 • Russell Vought, head of Trump's Office of Budget and Management, believes the president has the power to completely dismantle any aspect of the federal government he chooses ...

This may not be the gunslinging frontier of Red Dead Redemption, but this adventure map captures the feel of the Wild West. The smoothing ... This simple, 30-minute, point-and-click Minecraft ...